OPKO Health (NASDAQ:OPK) Lowered to Sell Rating by StockNews.com

StockNews.com lowered shares of OPKO Health (NASDAQ:OPK) from a hold rating to a sell rating in a research report released on Monday morning.

OPK has been the topic of a number of other reports. Barrington Research restated an “outperform” rating and set a $2.25 price objective on shares of OPKO Health in a research report on Thursday, May 1st. HC Wainwright restated a “buy” rating and set a $3.00 price target on shares of OPKO Health in a report on Monday, April 7th. Finally, JPMorgan Chase & Co. started coverage on OPKO Health in a research report on Friday, April 25th. They issued a “neutral” rating for the company. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $2.75.

OPKO Health Trading Down 1.8 %

Shares of OPK opened at $1.36 on Monday. The stock has a market capitalization of $913.31 million, a PE ratio of -7.16 and a beta of 1.42. The company’s fifty day moving average is $1.61 and its 200 day moving average is $1.57. The company has a debt-to-equity ratio of 0.30, a quick ratio of 2.69 and a current ratio of 2.97. OPKO Health has a fifty-two week low of $1.15 and a fifty-two week high of $2.04.

OPKO Health (NASDAQ:OPK) last issued its quarterly earnings data on Wednesday, April 30th. The biotechnology company reported ($0.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.03). The business had revenue of $149.90 million during the quarter, compared to analysts’ expectations of $163.13 million. OPKO Health had a negative return on equity of 9.76% and a negative net margin of 18.65%. The business’s quarterly revenue was down 13.7% on a year-over-year basis. During the same period in the previous year, the business earned ($0.12) earnings per share. Sell-side analysts expect that OPKO Health will post -0.25 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Phillip Md Et Al Frost acquired 200,000 shares of the business’s stock in a transaction dated Monday, March 17th. The shares were acquired at an average cost of $1.74 per share, with a total value of $348,000.00. Following the completion of the acquisition, the chief executive officer now owns 213,501,448 shares of the company’s stock, valued at approximately $371,492,519.52. This trade represents a 0.09 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Over the last 90 days, insiders acquired 767,434 shares of company stock valued at $1,238,312. 49.69% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On OPKO Health

A number of institutional investors have recently modified their holdings of the stock. Millennium Management LLC grew its stake in shares of OPKO Health by 85.3% during the 4th quarter. Millennium Management LLC now owns 4,588,526 shares of the biotechnology company’s stock worth $6,745,000 after purchasing an additional 2,112,382 shares during the period. Northern Trust Corp grew its position in OPKO Health by 4.7% during the fourth quarter. Northern Trust Corp now owns 3,697,774 shares of the biotechnology company’s stock valued at $5,436,000 after buying an additional 164,847 shares during the period. Lazard Asset Management LLC increased its holdings in OPKO Health by 143.6% in the fourth quarter. Lazard Asset Management LLC now owns 2,548,667 shares of the biotechnology company’s stock valued at $3,746,000 after buying an additional 1,502,342 shares in the last quarter. Two Sigma Investments LP increased its holdings in OPKO Health by 136.1% in the fourth quarter. Two Sigma Investments LP now owns 1,647,567 shares of the biotechnology company’s stock valued at $2,422,000 after buying an additional 949,671 shares in the last quarter. Finally, Nuveen Asset Management LLC raised its position in shares of OPKO Health by 42.3% in the fourth quarter. Nuveen Asset Management LLC now owns 1,432,404 shares of the biotechnology company’s stock worth $2,106,000 after acquiring an additional 425,484 shares during the period. Hedge funds and other institutional investors own 64.63% of the company’s stock.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.